ReviewMicroorganisms2022
Literature Review of Omicron: A Grim Reality Amidst COVID-19.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023.Communications medicine · 2025Review
- Article
- Assessing SARS-CoV-2 Testing Adherence in a University Town: Recurrent Event Modeling Analysis.JMIR public health and surveillance · 2024Article
- Changes in symptoms and characteristics of COVID-19 patients across different variants: two years study using neural network analysis.BMC infectious diseases · 2023Article
- Analysis of influencing factors of job demands of healthcare workers working in mobile cabin hospitals in China.Nursing open · 2023Article
- Review
- Doctors ranking through heterogeneous information: The new score functions considering patients' emotional intensity.Expert systems with applications · 2023Article
- An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.Progress in biophysics and molecular biology · 2023Review
- Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review.Neural regeneration research · 2023Review
- COVID-19 increased in Italian children in the autumn and winter 2021-2022 period when Omicron was the dominant variant.Acta paediatrica (Oslo, Norway : 1992) · 2023Article
- Twice evasions of Omicron variants explain the temporal patterns in six Asian and Oceanic countries.BMC infectious diseases · 2023Article
- Epidemic efficacy of Covid-19 vaccination against Omicron: An innovative approach using enhanced residual recurrent neural network.PloS one · 2023Article
- The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern.Advances in experimental medicine and biology · 2023Review
- A Computational Study of Carbazole Alkaloids from Murraya koenigii as Potential SARS-CoV-2 Main Protease Inhibitors.Applied biochemistry and biotechnology · 2023Article
- Clinical characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in Shanghai.Journal of medical virology · 2023Article
- The impact of maternal SARS-CoV-2 infection and COVID-19 vaccination on maternal-fetal outcomes.Reproductive toxicology (Elmsford, N.Y.) · 2022Review
- Changes in preventive behaviour after COVID-19 vaccination in Thailand: a cross-sectional study.BMC public health · 2022Article
- Assessing the Compliance of Dental Clinicians towards Regulatory Infection Control Guidelines Using a Newly Developed Survey Tool: A Pilot Cross-Sectional Study in India.Healthcare (Basel, Switzerland) · 2022Article
- Clinical features of SARS-CoV-2 Omicron BA.2; Lessons from previous observations - Correspondence.International journal of surgery (London, England) · 2022Article
- Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?Exploration (Beijing, China) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) first emerged in Wuhan city in December 2019, and became a grave global concern due to its highly infectious nature. The Severe Acute Respiratory Coronavirus-2, with its predecessors (i.e., MERS-CoV and SARS-CoV) belong to the family of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.